Abstracts tagged "Outcome measures"

Abstract Number: 0392 • ACR Convergence 2022
Performance of Clinical, Laboratory and Imaging Features for the Diagnosis of Axial Spondyloarthritis – A Systematic Literature Review
Ana Bento da Silva¹, Helena Lourenço², Sofia Ramiro³, Louise Falzon⁴, Jaime Branco⁵, Désirée van der Heijde⁶, Robert Landewé⁷ and Alexandre Sepriano⁸, ¹Rheumatology department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal, ²Serviço de Reumatologia, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁵Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁷Amsterdam University Medical Center, Meerssen, Netherlands, ⁸Leiden University Medical Centre, Portela Loures, Portugal
Background/Purpose: The Berlin algorithm for the diagnosis of axial spondyloarthritis (axSpA) was developed more than 15 years ago (2004). Since then, new studies suggest that…
Abstract Number: 0858 • ACR Convergence 2022
Predicting the Occurrence of Drug-Free Inactive Disease Two Years After Diagnosis of Non-Systemic Juvenile Idiopathic Arthritis
Melissa Mannion¹, Chen Chen², Olha Halyabar³, Susan Paetkau⁴, Tingting Qiu⁵ and Bin Huang⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Cincinnati Children's Hospital Medical Center, Taipei, Taiwan, ³Children's Hospital/Boston Medical Center, Boston, MA, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, Cinciannati, OH
Background/Purpose: The goal of treatment for juvenile idiopathic arthritis (JIA) is inactive disease (ID), but the optimal treatment for each patient to maximize ID and…
Abstract Number: 1260 • ACR Convergence 2022
Tenderness and Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis
Irina Gessl¹, Mihaela Popescu², Gabriela supp³, Thomas Deimel¹, Paul Studenic¹, Martina Durechova³, michael zauner³, Josef Smolen¹ and Peter Mandl¹, ¹Medical University of Vienna, Vienna, Austria, ²Department of Rheumatology, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada, ³Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: In inflammatory arthritis swelling is regarded as a sign of synovitis and is associated with radiographic progression. However, the association of tenderness with radiographic…
Abstract Number: 1496 • ACR Convergence 2022
Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met?
Sarah Yazji¹, Philip Helliwell², Andra Balanescu³, JUAN CANETE⁴, Emmanuelle Dernis⁵, Uta Kiltz⁶, Ying Ying Leung⁷, Ennio Lubrano⁸, Ana-Maria Orbai⁹, PENELOPE PALOMINOS¹⁰, Rossana Scrivo¹¹, Josef Smolen¹², Sandra Meisalu¹³, Maarten de Wit¹⁴, Laure Gossec¹⁵ and Laura Coates¹⁶, ¹University of Oxford, Oxford, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, ⁴Rheumatology Department, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁵LE MANS general hospital, LE MANS, France, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Rheumatology Department, Singapore General Hospital, Singapore, Singapore, ⁸Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy, ⁹Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹⁰Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ¹¹Rheumatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy, Roma, Rome, Italy, ¹²Medical University of Vienna, Vienna, Austria, ¹³East Tallinn Central Hospital, Tallinn, Estonia, ¹⁴Patient research partner, Amsterdam, Netherlands, ¹⁵Sorbonne Université, Paris, France, ¹⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: The Minimal Disease Activity (MDA) criteria evaluate PsA disease activity and response to treatment and are defined as meeting ≥5 criteria: tender joint count…
Abstract Number: 1952 • ACR Convergence 2022
Burden of Disease in Refractory Rheumatoid Arthritis
Kristin Wipfler¹, Bobby Kwanghoon Han², Urbano Sbarigia³, Federico Zazzetti⁴, Anna Sheahan⁵, Iris Lin⁶, Patricia Katz⁷, Evo Alemao⁸ and Kaleb Michaud⁹, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²Division of Rheumatology, University of Washington, Seattle, WA, ³Johnson & Johnson, Beerse, Belgium, ⁴Janssen Medical Affairs Global Services, LLC, Buenos Aires, Argentina, ⁵Janssen Research and Development, Chapel Hill, NC, ⁶Janssen, Horsham, PA, ⁷UCSF, San Rafael, CA, ⁸Janssen, Princeton, NJ, ⁹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Despite major advances in RA treatment and the improved outcomes that have been associated with the expanding number of advanced therapies available, a substantial…
Abstract Number: 2138 • ACR Convergence 2022
Real-world Persistence and Treatment Patterns in Psoriatic Arthritis Patients Treated with Anti-IL17 Therapy
BEATRIZ E. JOVEN¹, Concepción Fito Manteca², Enrique Rubio³, Enrique Raya Álvarez⁴, Alba Pérez⁵, Raquel Hernández⁶, Sara Manrique Arija⁷, Mercedes Núñez⁸, Silvia Díaz⁸, Luis Trancho⁸, Sebastian Moyano⁸, Alessandra Lacetera⁹, Noelia Alfaro-Oliver⁹ and Rosario Garcia-Vicuña¹⁰, ¹Hospital Universitario 12 de Octubre, Madrid, Spain, ²Hospitalario de Navarra, Pamplona, Spain, ³Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁴Hospital Universitario San Cecilio, Granada, Spain, ⁵Hospital Puerta del Mar, Cádiz, Spain, ⁶Virgen de Valme University Hospital, Sevilla, Spain, ⁷Hospital Regional Universitario Málaga, Málaga, Spain, ⁸Lilly, Alcobendas, Spain, ⁹OXON Epidemiology, Madrid, Spain, ¹⁰Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain
Background/Purpose: Interleukin-17A inhibitors (anti-IL17) have provided an additional treatment option in the management of the psoriatic arthritis (PsA). This study aims to describe the patient…
Abstract Number: 0172 • ACR Convergence 2022
Clinical Characteristics and Outcomes of Inflammatory Myositis Related Interstitial Lung Disease: A 15 Year Retrospective Study
Ian Ward¹, Elizabeth Pepper² and Geoffrey Loh², ¹United States Army, Evans, GA, ²DDEAMC, Ft. Gordon, GA
Background/Purpose: Interstitial lung disease (ILD) is a common complication of Idiopathic Inflammatory Myopathy (IIM). This extra-muscular manifestation is a significant source of morbidity and has…
Abstract Number: 0418 • ACR Convergence 2022
Real World Evidence on Disease Activity in Patients with Ankylosing Spondylitis Treated with Tumour Necrosis Factor Inhibitors and/or Nonsteroidal Anti-Inflammatory Drugs in Routine Care
Jan Brandt-Juergens¹, Judith Haschka², Richard Finsterwalder³, Aurélie Casier⁴, Angela Kill⁵ and Stéphanie Dierckx⁶, ¹Rheumatologische Schwerpunktpraxis, Berlin, Germany, ²Karl Landsteiner Institute for Gastroenterology and Rheumatology Rheuma-Zentrum Wien-Oberlaa, Vienna, Austria, ³Novartis Pharma GmbH, Vienna, Austria, ⁴N.V. Novartis Pharma S.A., Vilvoorde, Belgium, ⁵Novartis Pharma GmbH, Nuremberg, Germany, ⁶CHU UCL Namur- Site Godinne, Yvoir, Belgium
Background/Purpose: Ankylosing Spondylitis (AS) is an inflammatory rheumatic disease affecting the axial skeleton (1), with a prevalence of up to 0.5% in Europe (2; 3),…
Abstract Number: 0890 • ACR Convergence 2022
Long Term Efficacy of a 2-year MRI Treat-to-target Treatment Strategy on Disease Activity, MRI Inflammation and Physical Function in Rheumatoid Arthritis Patients in Clinical Remission: Five Year Follow-up of the IMAGINE-RA Cohort
Signe Møller-Bisgaard¹, Kim Hørslev-Petersen², Daniel Glinatsi³, Bo Ejbjerg⁴, Merete Lund Hetland⁵, Jakob Møllenbach Møller⁶, Robin Christensen⁷, Sabrina Mai Nielsen⁸, Mikael Boesen⁹, Kristian Stengaard-Pedersen¹⁰, Ole Rintek Madsen¹¹, Bente Jensen¹², Jan Alexander Villadsen¹³, Ellen Margrethe Hauge¹⁰, Oliver Hendricks², Hanne Merete Lindegaard¹⁴, Niels Steen Krogh¹⁵, Anne Grethe Jurik¹⁶, Henrik Thomsen¹⁷ and Mikkel Østergaard¹⁸, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ²Department of Rheumatology, Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁴Department of Rheumatology, Slagelse Hospital, Slagelse, Denmark, ⁵Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark, ⁶Department of Radiology, Herlev-Gentofte Hospital, Copenhagen, Denmark, ⁷Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ⁸The Parker Institute, Section for Biostatistics and Evidence-Based Research, Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, ⁹Department of Radiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark, ¹⁰Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ¹¹Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Herlev-Gentofte, Copenhagen, Denmark, ¹²Center for Rheumatology and Spine Diseases, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark, ¹³Department of Rheumatology, Silkeborg Hospital, Silkeborg, Denmark, ¹⁴Department of Rheumatology, Odense University Hospital, Odense, Denmark, ¹⁵ZiteLab ApS, Frederiksberg, Denmark, ¹⁶Department of Radiology, Aarhus University Hospital, Aarhus, Denmark, ¹⁷Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, Denmark, ¹⁸Rigshospitalet, University of Copenhagen, Glostrup, Denmark
Background/Purpose: Targeting MRI remission in rheumatoid arthritis (RA) patients in clinical remission may improve long term clinical, functional and MRI outcomes. The purpose of the…
Abstract Number: 1261 • ACR Convergence 2022
Scoring Structural Damage in Rheumatoid Arthritis by Ultrasound: Results from a Delphi Process and Web-Based Reliability Exercise by the OMERACT Ultrasound Working Group
Peter Mandl¹, Irina Gessl¹, Georgios Filippou², Silvia Sirotti³, Lene Terslev⁴, Carlos Pineda⁵, Helen Keen⁶, Marina Backhaus⁷, David Bong⁸, Edoardo Cipolletta⁹, Paz Collado¹⁰, Christian Dejaco¹¹, Andrea Delle Sedie¹², Christina Duftner¹³, Hilde Berner Hammer¹⁴, Annmaria Iagnocco¹⁵, Zunaid Karim¹⁶, Esperanza Naredo¹⁷, Wolfgang Schmidt¹⁸, Marcin Szkudlarek¹⁹, Giorgio Tamborrini²⁰, Priscilla Wong²¹, Emilio Filippucci⁹, Peter Balint²² and Maria-Antonietta D'Agostino²³, ¹Medical University of Vienna, Vienna, Austria, ²Rheumatology Department, Luigi Sacco University Hospital, Siena, Italy, ³Università degli Studi di Milano, Milano, Italy, ⁴Copenhagen University Hospital Glostrup, Glostrup, Denmark, ⁵Instituto Nacional de Rehabilitacion, Ciudad de México, Mexico, ⁶University of Western Australia, Perth, Australia, ⁷Park-Klinik Weissensee Academic Hospital of the Charité, Berlin, Germany, ⁸Instituto Poal de Reumatologia, Universitat de Barcelona, Barcelona, Spain, ⁹Polytechnic University of Marche, Rheumatology Unit, Department of Clinical and Molecular Sciences, "Carlo Urbani" Hospital, Jesi, Italy, ¹⁰Division of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain, ¹¹Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ¹²University of Pisa, Pisa, Pisa, Italy, ¹³Department of Internal Medicine, Medical University of Innsbruck, Innsbruck, Austria, ¹⁴Diakonhjemmet hospital, Jar, Norway, ¹⁵Academic Rheumatology Centre, University of Turin, Turin, Italy, ¹⁶Department of Rheumatology, Mid Yorkshire NHS Trust, Yorkshire, United Kingdom, ¹⁷Hospital General Universitario Gregorio Marañón and Complutense University, Madrid, Spain, ¹⁸Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology, Berlin-Buch, Berlin, Germany, ¹⁹Department of Rheumatology, Copenhagen University Hospital at Køge, Copenhagen, Denmark, ²⁰Ultrasound Center and Institute for Rheumatology, Basel, Switzerland, ²¹Division of Rheumatology, The Chinese University of Hong Kong, Hong-Kong, Hong Kong, ²²3rd. Department of Rheumatology, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ²³Catholic University of Sacred Heart, Roma, Italy
Background/Purpose: Structural damage in rheumatoid arthritis (RA) includes bone erosions, cartilage changes, and joint malalignment; historically evaluated with conventional radiography. Ultrasound (US) has been shown…
Abstract Number: 1499 • ACR Convergence 2022
The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control in Patients with Axial Spondyloarthritis: A Study from the CorEvitas PsA/SpA Registry
Philip J Mease¹, Robert McLean², Taylor Blachley², Nicole Middaugh², Manish Mittal³, Jerry Clewell³, Heather Jones⁴ and Alexis Ogdie⁵, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³AbbVie, Inc., North Chicago, IL, ⁴AbbVie, Inc., Chicago, IL, ⁵Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Axial spondyloarthritis (AxSpA) is a chronic inflammatory disease characterized by inflammatory back pain, morning stiffness, and reduced functional capacity. Approved therapies for AxSpA include…
Abstract Number: 1960 • ACR Convergence 2022
Impact of Delaying Initiation of Methotrexate by One Month on the Outcome of RA at One Year
Theresa Than¹, Emmanuelle Dernis², Olivier BROCQ³, Bruno Fautrel⁴, Helena HUGUET⁵, Liana Euller-Ziegler⁶, Lindsay BUSTAMENTE-CENCI⁶, Olivier Vittecoq⁷, Marie-christine PICOT⁵, Cédric Lukas⁸, Claire DAIEN⁹, Charlotte Hua¹⁰, Marlène Genty⁵, Helene Che⁵, Anouck REMY-MOULARD¹¹, Frederic LIOTE¹², Martin Soubrier¹³, Cécile GAUJOUX-VIALA¹⁴, Arnaud Constantin¹⁵, Alain Saraux¹⁶, Emilie Ducourau¹⁷, Stephanie RIST¹⁸, CARINE SALLIOT¹⁹, Nada IBRAHIM-NASSER¹⁸, Clara qUINTEN¹⁸, Vincent Goeb²⁰ and Jacques Morel¹, ¹University and CHU Montpellier, Montpellier, France, ²LE MANS general hospital, LE MANS, France, ³Centre hospitalier Princesse-Grace, Monaco, France, ⁴Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ⁵CHU Montpellier, Montpellier, France, ⁶CHRU Nice, Nice, France, ⁷CHU de Rouen, ROUEN, France, ⁸University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, ⁹University Hospital, Saint-Gély-du-Fesc, France, ¹⁰La Lettre du Rhumatologue, Paris, France, ¹¹CHU Montpellier, Montpellier, Chad, ¹²University of Paris, Paris, France, ¹³Gabriel-Montpied Hospital, Clermont-Ferrand, France, ¹⁴CHU Nîmes, Univ Montpellier (IDESP), Nîmes, France, ¹⁵Toulouse University Hospital, Toulouse, France, ¹⁶CHU Brest, Brest, France, ¹⁷CH Orleans, Chambray Les Tours, France, ¹⁸CH orleans, Orleans, France, ¹⁹CHR orleans, Orleans, France, ²⁰CHU Amiens, Amiens, France
Background/Purpose: It is recommended that vaccinations should be performed prior to start methotrexate (MTX) knowing that delaying initiation of background therapy may have an impact…
Abstract Number: 2139 • ACR Convergence 2022
Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial
Iain B McInnes¹, Philipp Sewerin², Mohamed Sharaf³, Michela Efficace⁴, May Shawi⁵, Michelle Perate⁶, Miriam Zimmermann⁷ and Laura Coates⁸, ¹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ²Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, ³Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, ⁴Janssen Cilag SpA, Imperia, Italy, ⁵Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, ⁷Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁸Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody targeting the IL-23 p19 subunit. In the Phase 3b COSMOS trial (NCT03796858), GUS significantly improved disease signs/symptoms…
Abstract Number: 0191 • ACR Convergence 2022
Patient-reported Outcomes to Assess Dyspnea in Connective Tissue Diseases, Interstitial Lung Disease and Pulmonary Hypertension, a Systematic Literature Review of Measurement Properties
Jacqueline Lemmers¹, Madelon Vonk² and Els Ende, van den³, ¹Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Radboudumc, Nijmegen, Netherlands
Background/Purpose: This COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN)-based systematic review aims to identify and summarize the quality of measurement properties of…
Abstract Number: 0421 • ACR Convergence 2022
Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis by Prior bDMARD Treatment: Analysis of a Phase 3 Trial
Atul Deodhar¹, Helena Marzo-Ortega², Joseph Wu³, Cunshan Wang³, Oluwaseyi Dina⁴, Keith S Kanik³, Lara Fallon⁵ and Lianne Gensler⁶, ¹Oregon Health & Science University, Portland, OR, USA, Portland, OR, ²Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Montréal, QC, Canada, ⁶Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Prior exposure to biologic (b)DMARD therapy of patients (pts) with AS may influence treatment response.1-3 Tofacitinib is an oral JAK inhibitor for the treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].